NextCure Q1 net loss narrows to $11.0M; LNCB74 ADC Phase 1 dosing cohort 3

NextCure, Inc.

2025-Q1 EPS reported -$0.39

Cash $55.9M as of March 31, 2025, down from $68.6M; expected runway into H2 2026.
Net loss $11.0M vs $17.1M YoY; R&D expense $7.9M vs $11.4M YoY due to 2024 restructuring.
LNCB74 (B7-H4 ADC) Phase 1 cleared cohort 2, dosing cohort 3; backfill cohorts planned H2 2025.
Proof-of-concept data readout for LNCB74 planned in first half of 2026.
Preclinical NC181 (Alzheimer's) and NC605 (osteogenesis imperfecta) seeking partners; IND filings possible in 12-18 months if funded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.